TATX-03a

**TATX-03a** is a preclinical, fixed-combination PolyTope antibody therapy developed by ImmunoPrecise Antibodies for prevention and treatment of COVID-19. It combines four fully human anti-SARS-CoV-2 spike monoclonal antibodies—2-A6, 22-D9, 22-E7, and 23-H7—that recognize distinct, non-overlapping spike epitopes. Although the individual component antibodies were non-neutralizing in the reported selection strategy, their combination produced synergistic virus neutralization and reduced viral burden and respiratory-tract inflammation in SARS-CoV-2-challenged Syrian hamsters in both prophylactic and therapeutic settings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1715925/000115752321000798/a52446845_ex991.htm))

Other names

TATX-03a PolyTope TherapyTATX03a PolyTope TherapyTATX 03a PolyTope Therapy